BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beck KR, Kim N, Khalili M. Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience. Dig Dis Sci 2016;61:3602-8. [PMID: 27743164 DOI: 10.1007/s10620-016-4340-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Turgeon MK, Lee RM, Gamboa AC, Yopp A, Ryon EL, Goel N, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Maithel SK, Russell MC. Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study. HPB (Oxford) 2021;23:422-33. [PMID: 32778389 DOI: 10.1016/j.hpb.2020.07.012] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Serumondo J, Penkunas MJ, Niyikora J, Ngwije A, Kiromera A, Musabeyezu E, Umutesi J, Umuraza S, Musengimana G, Nsanzimana S. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators. BMC Public Health 2020;20:946. [PMID: 32546216 DOI: 10.1186/s12889-020-09000-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Khalili M, Powell J, Park HH, Bush D, Naugle J, Ricco M, Magee C, Braimoh G, Zevin B, Fokuo JK, Masson CL. Shelter-Based Integrated Model Is Effective in Scaling Up Hepatitis C Testing and Treatment in Persons Experiencing Homelessness. Hepatol Commun 2021. [PMID: 34628726 DOI: 10.1002/hep4.1791] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yek C, de la Flor C, Marshall J, Zoellner C, Thompson G, Quirk L, Mayorga C, Turner BJ, Singal AG, Jain MK. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study. BMC Med 2017;15:204. [PMID: 29151365 DOI: 10.1186/s12916-017-0969-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
5 Kim NJ, Locke CJ, Park H, Magee C, Bacchetti P, Khalili M. Race and Hepatitis C Care Continuum in an Underserved Birth Cohort. J Gen Intern Med 2019;34:2005-13. [PMID: 30238404 DOI: 10.1007/s11606-018-4649-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
6 Stewart RA, MacDonald BR, Chu TC, Moore JD, Fasanmi EO, Ojha RP. Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population. Dig Dis Sci 2018;63:3233-40. [PMID: 30014226 DOI: 10.1007/s10620-018-5205-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Powell J, Ricco M, Naugle J, Magee C, Hassan H, Masson C, Braimoh G, Zevin B, Khalili M. Adherence to Hepatitis C Therapy in a Shelter-Based Education and Treatment Model Among Persons Experiencing Homelessness. Open Forum Infect Dis 2021;8:ofab488. [PMID: 34651053 DOI: 10.1093/ofid/ofab488] [Reference Citation Analysis]
8 Khalili M, Wong RJ. Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. Dig Dis Sci 2018;63:3250-2. [PMID: 30311153 DOI: 10.1007/s10620-018-5316-9] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
9 Librelotto CS, Souza AP, Álvares-DA-Silva MR, Simon D, Dihl RR. Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line. An Acad Bras Cienc 2021;93:e20200632. [PMID: 34586319 DOI: 10.1590/0001-3765202120200632] [Reference Citation Analysis]
10 Monllor-Nunell MT, Sanchez-Lloansí M, Dosal-Galguera A. Direct antiviral treatment in patients with hepatitis C virus: Implementation of a nurse telephone consultation. Enferm Clin 2017;27:387-91. [PMID: 29074167 DOI: 10.1016/j.enfcli.2017.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
11 Khalili M, Wong RJ. Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. Dig Dis Sci 2018;63:3250-2. [PMID: 30311153 DOI: 10.1007/s10620-018-5316-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
12 Eckardt P, Niu J, Savage A, Griffin T, Sherman E. Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital. J Int Assoc Provid AIDS Care 2019;18:2325958219835590. [PMID: 30922148 DOI: 10.1177/2325958219835590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kim NJ, Magee C, Cummings C, Park H, Khalili M. Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population. Hepatol Commun 2018;2:1274-83. [PMID: 30288480 DOI: 10.1002/hep4.1246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
14 Beck KR, Kim NJ, Khalili M. Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans. Ann Hepatol 2018;17:413-8. [PMID: 29735789 DOI: 10.5604/01.3001.0011.7385] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
15 Nsanzimana S, Penkunas MJ, Liu CY, Sebuhoro D, Ngwije A, Remera E, Umutesi J, Ntirenganya C, Mugeni SD, Serumondo J. Effectiveness of Direct-Acting Antivirals for the treatment of chronic hepatitis C in Rwanda: A retrospective study. Clin Infect Dis 2020:ciaa701. [PMID: 32505127 DOI: 10.1093/cid/ciaa701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]